Patents by Inventor Norma J. Ofsthun

Norma J. Ofsthun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9078969
    Abstract: A dialysate regeneration system for removing contaminants from spent dialysate according to this invention includes a dialysate circulation flow path including a pump that pumps spent dialysate through the dialysate circulation flow path, a first cartridge adapted to remove contaminants from the spent dialysate, including a first cleaning solution inlet and a first cleaning solution outlet, a second cartridge adapted to remove urea from the spent dialysate, the second cartridge including semi-permeable hollow fibers adapted for transport of urea across the walls of the semi-permeable hollow fibers and adapted to retain at least calcium, magnesium, and sodium ions in the spent dialysate, and including a second cleaning solution inlet and a second cleaning solution outlet.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: July 14, 2015
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Norma J. Ofsthun, Harold F. Sandford, Amanda K. Stennett, Jiunn Yeong Teo, Cheryl Ford, Benjamin J. Lipps, Michael James Beiriger
  • Patent number: 8999169
    Abstract: The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 7, 2015
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Frank A. Gotch, Benjamin J. Lipps, Peter Kotanko, Nathan W. Levin, Amanda K. Stennett, Norma J. Ofsthun
  • Patent number: 8822225
    Abstract: A method of identifying a patient who is non-compliant with prescribed diet and/or phosphate binder regimen calculates a phosphorus-protein ratio (PPR) by calculating the patient's protein intake, measuring the patient's serum phosphorus concentration, and estimating the amount of phosphorus removed by the patient's kidneys from measured residual urea clearance. The PPR is the ratio between the total amount of phosphorus removed from the patient and the patient's protein intake. The method enables identifying a patient that is non-compliant with prescribed diet and/or phosphate binder regimen if the PPR is outside of an acceptable range.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: September 2, 2014
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Frank A. Gotch, Amanda K. Stennett, Norma J. Ofsthun
  • Patent number: 8777892
    Abstract: A portable peritoneal dialysis system for a patient includes an inlet port for providing inflow to the patient's peritoneal cavity, an outlet port for providing outflow from the patient's peritoneal cavity, and a volume of dialysate for flow into and out of the patient's peritoneal cavity, thereby removing from the dialysate uremic waste metabolites that have diffused into the dialysate. The portable peritoneal dialysis system also includes a closed liquid flow loop, including a pump, for flowing the dialysate into and out of the patient's peritoneal cavity, and an organic- and phosphate-removing stage, including at least one replaceable cartridge in the closed liquid flow loop, the cartridge containing material for removing organic compounds and phosphate from dialysate removed from the patient's peritoneal cavity.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: July 15, 2014
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Harold F. Sandford, Norma J. Ofsthun, Amanda K. Stennett, Jiunn Yeong Teo, Cheryl Ford, Benjamin J. Lipps
  • Patent number: 8715221
    Abstract: The present invention relates to a wearable peritoneal dialysis system and a replaceable cartridge in the wearable peritoneal dialysis system that regenerates the peritoneal dialysis solution without removing essential ions from the solution and, consequently, the patient. The invention also relates to methods of removing uremic waste metabolites from a patient using the wearable peritoneal dialysis system. A source of one or more enzymes that degrades uremic waste metabolites can be administered orally in conjunction with use of the wearable peritoneal dialysis system such that the load of toxins needing to be eliminated by the wearable peritoneal dialysis system is reduced. The wearable peritoneal dialysis system is meant to operate continuously or semi-continuously, its components small and light enough that it can be comfortably worn by a patient constantly, without burden.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: May 6, 2014
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Conor Curtin, Benjamin J. Lipps, Norma J. Ofsthun, Harold F. Sandford
  • Publication number: 20120184036
    Abstract: A method of identifying a patient who is non-compliant with prescribed diet and/or phosphate binder regimen calculates a phosphorus-protein ratio (PPR) by calculating the patient's protein intake, measuring the patient's serum phosphorus concentration, and estimating the amount of phosphorus removed by the patient's kidneys from measured residual urea clearance. The PPR is the ratio between the total amount of phosphorus removed from the patient and the patient's protein intake. The method enables identifying a patient that is non-compliant with prescribed diet and/or phosphate binder regimen if the PPR is outside of an acceptable range.
    Type: Application
    Filed: October 1, 2010
    Publication date: July 19, 2012
    Inventors: Frank A. Gotch, Amanda K. Stennett, Norma J. Ofsthun
  • Patent number: 8012118
    Abstract: The present disclosure relates to a wearable dialysis system and method for removing uremic waste metabolites and fluid from a patient suffering from renal disease. Uremic waste metabolites can be removed by a wearable peritoneal dialysis device that regenerates the peritoneal dialysis solution without removing positively charged, essential ions from the solution and, consequently, the patient. Fluids can be removed from the blood of the patient by an implantable fluid removing device. Fluids are delivered to the bladder and preferably removed from the body of the patient through urination. The wearable dialysis system may be operated continuously or semi-continuously and be comfortably adapted to the body of the patient while allowing the patient to perform normal activities.
    Type: Grant
    Filed: August 23, 2007
    Date of Patent: September 6, 2011
    Assignee: Fresenius Medical Care Holdings, Inc.
    Inventors: Conor Curtin, Benjamin J. Lipps, Norma J. Ofsthun, Harold F. Sandford, Amanda Stennett, David Updyke
  • Publication number: 20110060273
    Abstract: A dialysate regeneration system for removing contaminants from spent dialysate according to this invention includes a dialysate circulation flow path including a pump that pumps spent dialysate through the dialysate circulation flow path, a first cartridge adapted to remove contaminants from the spent dialysate, including a first cleaning solution inlet and a first cleaning solution outlet, a second cartridge adapted to remove urea from the spent dialysate, the second cartridge including semi-permeable hollow fibers adapted for transport of urea across the walls of the semi-permeable hollow fibers and adapted to retain at least calcium, magnesium, and sodium ions in the spent dialysate, and including a second cleaning solution inlet and a second cleaning solution outlet.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 10, 2011
    Applicant: Fresenius Medical Care Holdings, Inc.
    Inventors: Norma J. Ofsthun, Harold F. Sandford, Amanda K. Stennett, Jiunn Yeong Teo, Cheryl Ford, Benjamin J. Lipps
  • Publication number: 20100114012
    Abstract: A portable peritoneal dialysis system for a patient includes an inlet port for providing inflow to the patient's peritoneal cavity, an outlet port for providing outflow from the patient's peritoneal cavity, and a volume of dialysate for flow into and out of the patient's peritoneal cavity, thereby removing from the dialysate uremic waste metabolites that have diffused into the dialysate. The portable peritoneal dialysis system also includes a closed liquid flow loop, including a pump, for flowing the dialysate into and out of the patient's peritoneal cavity, and an organic- and phosphate-removing stage, including at least one replaceable cartridge in the closed liquid flow loop, the cartridge containing material for removing organic compounds and phosphate from dialysate removed from the patient's peritoneal cavity.
    Type: Application
    Filed: November 2, 2009
    Publication date: May 6, 2010
    Inventors: Harold F. Sandford, Norma J. Ofsthun, Amanda K. Stennett, Jiunn Yeong Teo, Cheryl Ford, Benjamin J. Lipps
  • Patent number: 5871649
    Abstract: The present invention provides an improved affinity membrane device and method for the effective removal of target molecules in plasma. The affinity membrane device is designed for use in an extracorporeal blood circuit and can be employed concurrently with other therapeutic processes for the purification of blood. The device of the present invention consists of hollow fiber membranes having specified dimensions and transfer properties, ligand immobilized to the pore surface of the hollow fibers, and a housing to encase the hollow fibers and allow appropriate entry and exit of the blood. In a preferred embodiment, specific immobilization chemistries are utilized to attach the ligands to the hollow fibers for optimal function.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: February 16, 1999
    Assignee: Baxter International Inc.
    Inventors: Norma J. Ofsthun, Paul J. Soltys, Gretchen A. Kunas
  • Patent number: 5868936
    Abstract: The present invention provides an improved affinity membrane device and method for the effective removal of target molecules in plasma. The affinity membrane device is designed for use in an extracorporeal blood circuit and can be employed concurrently with other therapeutic processes for the purification of blood. The device of the present invention consists of hollow fiber membranes having specified dimensions and transfer properties, ligand immobilized to the pore surface of the hollow fibers, and a housing to encase the hollow fibers and allow appropriate entry and exit of the blood. In a preferred embodiment, specific immobilization chemistries are utilized to attach the ligands to the hollow fibers for optimal function.
    Type: Grant
    Filed: June 20, 1996
    Date of Patent: February 9, 1999
    Assignee: Baxter International Inc.
    Inventors: Norma J. Ofsthun, Paul J. Soltys, Gretchen A. Kunas
  • Patent number: 5527467
    Abstract: The invention provides dual-skinned membranes useful as one way or rectifying membranes which reduce back filtration of solute molecules in dialysis and which improve nutrient supply and product recovery in membrane bioreactors. The membranes are dual-skinned polymeric materials preferably in the form of hollow fibers. The membranes have skins of polymer on the opposite sides with differing permeability to solutes and sieving coefficient characteristics. The skin on each side have pores that are invisible at 10,000 times magnification, the microporous structure between said skins contains pores capable of retaining solutes in a molecular weight range of about 5000 to 200000 in an increased concentration between the interior and the exterior skins. Improved dialysis devices are formed by using bundles of the hollow fiber membranes as a dialysis means having rectifying properties.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: June 18, 1996
    Assignee: Baxter International Inc.
    Inventors: Norma J. Ofsthun, Lee W. Henderson, Richard I. Brown, Robin G. Pauley